Physician profile
Beth G Diamond
NPI 1598753097
$4,039.12
in general payments reported to CMS, 2019-2025
27 companies · $996 in 2025
The $996 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $760 · 2020: $235 · 2021: $47.05 · 2022: $405 · 2023: $652 · 2024: $945 · 2025: $996.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,497 · Education: $94.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,497.35 |
| Education | $94.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,020.27 | 2019-2025 | Skyrizi, Rinvoq |
| Janssen Biotech, INC. | $399.19 | 2019-2025 | Tremfya |
| Novartis Pharmaceuticals Corporation | $282.92 | 2019-2025 | |
| Lilly USA, LLC | $279.58 | 2019-2025 | Ebglyss, Olumiant, Taltz |
| Regeneron Healthcare Solutions, INC. | $222.26 | 2022-2025 | Dupixent |
| Genzyme Corporation | $217.10 | 2019-2024 | |
| Hill Dermaceuticals, INC. | $208.40 | 2024 | Tolak |
| E.R. Squibb & Sons, L.L.C. | $176.83 | 2023-2024 | Sotyktu |
| Galderma Laboratories, L.P. | $137.20 | 2019-2024 | Aklief |
| Almirall LLC | $133.48 | 2019-2025 | Klisyri, Seysara |
| Pfizer INC. | $132.97 | 2019-2023 | |
| Allergan, INC. | $129.71 | 2019-2020 | |
| Dermavant Sciences, INC. | $110.71 | 2023-2024 | Vtama |
| Celgene Corporation | $88.67 | 2019 | |
| Amgen INC. | $82.57 | 2022-2025 | Otezla |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Strata Skin Sciences, INC. | $68.39 | 2019-2025 | Xtrac |
| Organon LLC | $60.39 | 2025 | Vtama |
| Sun Pharmaceutical Industries INC. | $45.20 | 2022-2025 | |
| Leo Pharma INC. | $44.45 | 2024-2025 | Adbry |
| Ucb, INC. | $40.17 | 2023-2024 | Cimzia, Bimzelx |
| Epi Health, LLC | $39.49 | 2019 | |
| Incyte Corporation | $36.29 | 2024-2025 | Opzelura |
| Mayne Pharma Commercial LLC | $24.57 | 2023 | |
| Arcutis Biotherapeutics, INC. | $17.76 | 2025 | Zoryve |
| Sebela Pharmaceuticals INC. | $17.69 | 2023 | Naftin |
| Glenmark Therapeutics INC. | $12.00 | 2019 | |
| Mission Pharmacal Company | $10.86 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Beth Diamond listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.